

TRUFFLE CAPITAL LAUNCHES ITS BIOMEDTECH ACCELERATOR IN THE HEART OF PARIS

Paris, 28 September 2023 – Truffle Capital, one of Europe's leading venture capital firms and founder or co-founder of French companies that have developed breakthrough innovations in the life sciences, such as Abivax (treatment of inflammatory diseases), Carbios (infinite biorecycling of plastics), Carmat (total artificial heart), Symetis (heart valves) and Vexim (spinal implants), is inaugurating its BioMedTech start-up accelerator in Paris, a unique place where radical medical innovation can work to improve health..

Dr. Philippe Pouletty, co-founder and managing director of Truffle Capital, said:

« With its BioMedTech Accelerator, Truffle Capital brings together the best skills and expertise in interventional medical device technologies in a single location. There are strong synergies between the companies, which benefit from shared skills. The aim is to help create a sector of excellence in France and build French and European leaders in MedTechs. »

The *Truffle BioMedTech Accelerator* is moving into the BioPark in the 13th arrondissement of Paris. Together with its sites in Nice, Lyon and Marseille, it comprises a total of 1,800 m² of space dedicated to research and development, housing a staff of 70, mainly researchers, engineers and doctors.

They are developing radical innovations for the treatment of diseases that affect the whole world, such as obesity (700 million obese people worldwide), stroke (the leading cause of death in the world) and gout (40 million sufferers worldwide).

The *Truffle BioMedTech Accelerator* welcomes seven emblematic BioMedtech start-ups:

ArteDrone

ArteDrone specialises in absolute emergency post-stroke intervention. The company is developing microrobots capable of autonomously guiding themselves through the cerebral vascular network of a patient who has suffered a stroke in order to urgently remove the clot blocking a cerebral artery. The microrobots are controlled remotely by external magnetic fields. The system is controlled by a software platform using the latest Artificial Intelligence and robotics techniques.

BariaTek

BariaTek is dedicated to the development of innovative medical devices designed to fight against obesity and diabetes, two pandemics affecting more than a billion patients worldwide. These minimally invasive devices are implanted endoscopically in just a few minutes and reproduce the effects of obesity surgery (or bariatric surgery).

Caranx Medical

Caranx Medical's mission is to design and develop new intelligent and autonomous surgical robots, combining artificial intelligence and robotic-assisted intervention to support surgeons and improve patient outcomes. The first applications targeted are aortic valve replacement (TAVI) and the endoscopic treatment of obesity.

HoliStick Medical

HoliStick is helping to combat anomalies that can cause strokes, by developing a transcatheter patch that makes it possible to 'close' these anomalies in a mini-invasive way, where current closure devices take up a lot of space in the heart, are metallic and make interventions difficult. HoliStick offers a non-metallic, minimalist implant that takes up very little space.

PK MED

PK MED offers therapeutic solutions for the local treatment of pain in inflammatory joint diseases and tissue regeneration, using 3D implants for example.

Skinosive

Skinosive is a dermo-cosmetics company that is developing a technique to make UV filters in sunscreens safer (preventing potentially toxic UV filters from being absorbed by the skin) and more durable (lasting all day) in a new generation of sun protection.

With a network built up over 25 years with the world's leading academic and clinical research centers and internationally recognized medical experts, the start-ups in the Truffle BioMedTech Accelerator attract talent from the best universities as well as cutting-edge companies in fields as promising as medical robotics, artificial intelligence, connected prostheses and intelligent drug delivery.

Through its accelerator, Truffle Capital aims to create a pioneering and leading center for research and innovation in medical technologies that are revolutionizing practices, saving lives and contributing to the growth of the French and European healthcare industries.

About Truffle Capital

Founded in 2001, Truffle Capital is an independent European venture capital firm specializing in disruptive technologies in the Life Sciences (Medtech and Biotech) and IT (Fintech and Insurtech) sectors. Truffle Capital's mission is to support the creation and development of innovative young companies capable of becoming tomorrow's leaders.

Chaired by Patrick Kron and managed by Dr Philippe Pouletty and Bernard-Louis Roques, Co-founders and Managing Directors, Truffle Capital manages assets of €600m. It has raised more than €1.1 billion since its creation and has supported more than 75 companies in the life sciences and digital technologies sectors.

<https://www.truffle.com/>

Truffle Capital Contact

Fanny Brugiere | fanny@truffle.com

Primatice Conseil

Thomas de Climens | thomasdeclimens@primatice.com

Armand Rigaudy | armandrigaudy@primatice.com